Across TCGA pan-cancer cohorts, COL6A4P1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated COL6A4P1 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher COL6A4P1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COL6A4P1 expression acts as an unfavorable survival marker.
SARC and UCEC are the cancer types where COL6A4P1 Mutation most reproducibly stratifies survival.